In the 4T1.2 syngeneic mouse breast model, ILC3s are recruited in the primary tumor through CCL21, and then they trigger tumor stromal cells to release CXCL13, which leads to the induction of lymphotoxin and receptor activator of nuclear factor κ-B ligand, that in turn promotes lymphangiogenesis and stimulate tumor cell motility (180). Here, CXCL13 is linked to neoplasm.